G1 Therapeutics Announces Initiation of Phase 1b/2 Clinical Trial of G1T38 in Combination with Tagrisso for EGFR-Mutant Non-Small Cell Lung Cancer
pharmaceutical investing Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update
pharmaceutical investing Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
Standard Uranium Initiates 2026 Drill Program at the Davidson River Uranium Project, Southwest Athabasca Basin
Nuvau Minerals commences PEA study to advance Matagami restart strategy, which includes a fully permitted critical metals mine
Pinnacle Receives More Positive Results from Second Round of Scoping Metallurgical Tests at El Potrero with Average Gold Recovery of 97.8% for the Main Dos de Mayo Vein
